Kornimate/medical-research-clean huggingface dataset:
cognitive and blood flow effects of mountain tea

Conditions: Cognitive Change; Affect; Blood Pressure; Neuroimaging

Summary: two doses (475 mg and 950 mg) of sideritis scardica (ss or 'mountain tea') are investigated for cognitive, mood, blood pressure and cerebral blood flow effects in a healthy group of 50-70 yr olds, both acutely and following 28 days of consumption.

the presence of polyphenols such as ferulic acid, chlorogenic acid and apigenin in sideritis scardica (ss or 'mountain tea') are likely responsible for the cognitive and mood effects of its consumption and this could be underpinned by the ability of such polyphenols to prevent monoamine neurotransmitter reuptake and to increase cerebral blood flow (cbf). the current randomised, placebo controlled, parallel groups study extends on the abovementioned small amount of literature; assessing both cognitive and mood outcomes in a sample of older (50-70 yrs) adults, as well as blood pressure (bp) and cbf, in a sub-sample, utilizing near-infrared spectroscopy (nirs). the above will be assessed acutely (pre-dose and 90- and 310-mins post dose) on day 1 and following 28 days consumption of either a placebo control, and active control of 240 mg ginkgo biloba, 475 mg ss or 950 mg ss.

Eligibility criteria:
inclusion criteria: * 50-70 yrs of age * no underlying health problem which would prevent engagement with the study exclusion criteria: * bmi \ 35 kg/m2 * high blood pressure (defined as systolic \> 159 mmhg or diastolic \> 90 mmhg) * smoking * food allergies or insensitivities * pregnancy or breast feeding * currently taking any medication (use of contraceptives/hormone replacements was not excluded) or dietary supplements which would contraindicate with the study * sleep disturbances and/or taking sleep aid medication * history of neurological, vascular or psychiatric illness * current diagnosis of anxiety or depression * migraines * recent history (within 12 months) of alcohol/substance abuse * disorder of the blood * heart disorder/history of vascular illness * respiratory disorder requiring regular medication * type i or ii diabetes * renal disease, hepatic disease or severe disease of the gastrointestinal tract - any health condition that would prevent the fulfilment of the study requirements
longitudinal screening for financial hardship to improve outcomes in patients with advanced cancer

Conditions: Advanced Cancer; Metastatic Cancer

Summary: the study aims to determine whether monthly remote digital financial hardship screening among adults with advanced/metastatic cancer, undergoing outpatient systemic therapy with non-curative intent, improves patient-centered outcomes, including financial worry, health-related quality of life (hrqol), symptom burden, patient-reported cancer treatment adherence, and exploratory outcomes of overall survival, patient-reported economic burden, patient-reported support received, patient-reported financial coping strategies, and health insurance literacy.

financial hardship is a common problem that affects patients treated for advanced cancer and leads to poor outcomes related to financial worry, health related quality of life (hrqol), symptom burden, treatment adherence, and overall survival. prior studies have shown that financial navigation may be an effective strategy to attenuate the impact of financial hardship. however, patients and clinicians have identified communication as a key barrier that prevents patients from being connected to sources of financial assistance. to address this critical gap in patient care, and based on strong preliminary data that financial hardship screening may improve patient outcomes, this financial hardship screening intervention will help connect patients to financial navigation resources. it is hypothesized that by connecting patients experiencing financial hardship with financial navigation resources, this intervention will lead to improved patient-centered outcomes.

Eligibility criteria:
inclusion criteria: 1. minimum age of 21 2. understands english and/or spanish 3. has a diagnosis of advanced/metastatic cancer 4. currently undergoing systemic therapy (enteral or parenteral) with non-curative intent 5. has been receiving treatment for at least 2 months 6. life expectancy of at least 6 months, in the opinion of the treating oncologist 7. cognitively able to give informed consent exclusion criteria: 1. under the age of 21 2. does not understand english or spanish 3. has cognitive deficits that would preclude understanding of consent form and/or questionnaires 4. undergoing treatment with curative intent (e.g., adjuvant chemotherapy for breast, lung, or ovarian cancer, primary curative therapy for testis cancer or lymphoma) 5. not undergoing systemic therapy (enteral or parenteral) with non-curative intent 6. receiving treatment for fewer than 2 months 7. life expectancy is less than 6 months, in the opinion of the treating oncologist

Keywords: financial toxicity
evaluation of right to play's positive child and youth development program in middle schools in hyderabad, pakistan

Conditions: Peer Violence; Depression

Summary: this is a rct conducted with 1752 children in 40 public middle schools in hyderabad pakistan with the goal of evaluating the effectiveness of the international non-governmental organisation right to play's positive child and youth development program on reducing peer violence perpetration and victimisation and child depression in a two arm trial where this intervention is compared to a no intervention arm.

peer violence is an important violence exposure for young adolescents and has been linked to later perpetration or experience of violence in intimate relationships. it is an obstacle to learning and may impact school students' mental health. prevention of peer violence requires an intervention that empowers youth and teaches them empathy and stronger social skills. the non-governmental organisation right to play operates in 18 countries and has a flagship programme that is used in all countries that has never been subject to most rigorous evaluation. it is a multi-faceted programme that has at its heart an intervention that is delivered throughout the school year in two 35 minute sessions games following activities from the manual red ball child play that focus on 4 areas of youth development: physical, cognitive, social, and emotional components. these structural activities are designed to improve critical thinking, confidence and resilience. they are complimented by a range of additional activities including junior leader training for selected promising young leaders, week long summary camps, sports days and activities to engage parents and members of the community. the main intervention is delivered by coaches employed by right to play and given a 3 week training initially, with subsequent regular refresher engagement. they are supported by junior leaders in the games after junior leader training. training to teachers on the intervention is also provided. a two-arm, cluster randomised controlled trial based in middle schools in hyderabad, sindh province, pakistan is evaluating this intervention. it is being conducted in 40 schools, half are boys schools (20) and half (20) girls'. twenty of the schools have been randomised to the intervention arm and twenty to the control (delayed intervention) arm. the outcomes will be addressed using quantitative methods with data collected from students in grade 6 at the start of the trial. these measures will be conducted pre-intervention and 12, and 24 month follow up periods.

Eligibility criteria:
inclusion criteria: * schools: single sex, public middle schools in hyderabad; willing to participate and commit time during the school day, twice a week, to the intervention sessions; having an outside playground or indoor space in which games could be played, and 35 or more students in the grade-6 class school student participants: enrolled in grade 6 in one of the study schools; informed consent from parent and child; able to read the national language urdu or provincial language sindhi exclusion criteria: * none
ginkgo biloba extract in the treatment of schizophrenia

Conditions: Schizophrenia

Summary: we investigated the effects of ginkgo biloba extract on the symptoms and cognitive functioning in patients with schizophrenia

objective: this study aimed to evaluate the effect of ginkgo biloba extract in the treatment of symptoms and cognitive functioning in 200? chronic patients with schizophrenia methods: 1. clinical trial: this is a randomized, double-blind and parallel controlled trial in the chronic patients with schizophrenia. the study consists of 12 weeks of double-blind treatment. 2. assessment procedures: 2.1 primary outcome variable: patients were assessed by two clinical trained staff, who were blind to the treatment protocols, by using the positive and negative syndrome scale (panss) to assess the psychopathology and repeatable battery for the assessment of neuropsychological status (rbans) to evaluation the cognitive functioning. patients were interviewed at screening, and at baseline, 4? weeks, 12? weeks. 2.2 side effects: the side effect rating scale (uku) was used to assess the side effect at baseline, 4? weeks, and 12? weeks. 2.3 weight gain measurement: weigh was measured every week.

Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia by two senior psychiatrists * between 18 and 60 years and han chinese * duration of symptoms at least 12 months * current psychotic symptoms of moderate severity exclusion criteria: * a diagnostic and statistical manual of mental disorders iv axis i diagnosis other than schizophrenia * documented disease of physical diseases including, but not limited to stroke, tumor, parkinson's disease, huntington's disease, seizure, epilepsy, history of brain trauma； * pregnant or breast-feeding female' * subjects who suffered from alcohol or illegal durg abuse/dependence

Keywords: schizophrenia ginkgo biloba extract cognition
ibuprofen versus ketorolac by mouth in the treatment of acute pain from osteoarticular trauma

Conditions: Acute Pain Due to Trauma

Summary: pain is the leading cause of access to the paediatric emergency department (ed) and present in up to 78% of cases. acute osteoarticular traumatic pain is often treated inadequately, and there is little data about the best treatment for children. the ibuprofen and ketorolac are respectively the most used and one of the most powerful nsaids. in literature, there is no direct comparison between those two medications. the objective of the study depends on the level of pain: * in severe traumatic acute pain (\>=7 points): to evaluate if ketorolac is superior to ibuprofen in the treatment of pain (n=130 children, 65 allocated to ketorolac and 65 to ibuprofen) * in moderate traumatic acute pain (\<7 points): to evaluate if ibuprofen is not inferior to ketorolac in the treatment of pain (n=120 children, 60 allocated to ketorolac and 60 to ibuprofen)


Eligibility criteria:
inclusion criteria: * age between 8 and 18 years * moderate to severe pain (value\>= 4 on the numerical rating scale / nrs) * pain due to a trauma at limbs that has occurred in the last 48 hours exclusion criteria: * administration of any analgesic in the previous 8 hours. * allergy known to one of the active ingredients * known hepatopathy or nephropathy * suspicion of violence by others * chronic use of painkillers * inability to report pain due to the presence of: intellectual disability (iq \<70); moderate-severe hearing loss; communication limitations such as patient mutism; unable to write; inability to speak italian * chronic neurological or metabolic diseases, * positive history for ease of bleeding, coagulation disorder or * thrombocytopenia * a history of gastritis or esophagitis in the last 30 days * multiple trauma * vascular-vascular deficit * state of pregnancy

Keywords: osteoarticular acute pain ketorolac ibuprofen
lipid metabolism in covid-19 severe pneumonia compared with severe pneumonia caused by other pathogen

Conditions: COVID-19 Severe Pneumonia; Severe Pneumonia Due to Other Pathogene

Summary: sars-cov 2 infection might be responsible for sever pneumonia. obesity seems to be a risk factor for severe sars-cov 2 pneumonia. lipid metabolism alteration are described with both obesity and sepsis. the aim of the present study was to describe association between lipid metabolism, obesity, sepsis inflammation and clinical outcome in covid-19 patient with severe pneumonia compared with severe pneumonia caused by other pathogenes.


Eligibility criteria:
inclusion criteria: * 2 of the following criteria: cough/ dyspnea/ spitting/ thoracic pain/ hyperthermia (\>=38 °c) hypothermia (\< 35°c) and new radiologic pulmonary infiltrate * at admission or within 48 hours following hospital admission * with 2 qsofa criteria: map =\ = 22, glasgow score \< 15 or on mechanical ventilation or under vasopressor * age \> 18 * affiliated to social security exclusion criteria: * pregnancy * immunodepression * pathology known to cause severe lymphopenia * hospitalisation within 3 month before inclusion and sepsis
band adhesions in relation to previous abdominal surgery

Conditions: Surgical Adhesions; Intestinal Obstruction; Surgery Induced Tissue Adhesions

Summary: this study investigates the prevalence of previous abdominal surgery in a cohort of patients operated for bowel obstruction and analyzes the causes of obstruction discovered at surgery.

postoperative intra-abdominal adhesions are a common cause of small bowel obstruction. the extent of adhesions has been assigned to the magnitude of previous surgery. in a county hospital, with a catchment population of 120 000 inhabitants, records of operations performed for bowel obstruction over a period of 70 months were retrieved. codes for bowel obstruction according to an international classification of diseases (icd-10) will include: intestinal adhesion with obstruction, other and unspecified intestinal obstruction, intestinal obstruction and peritoneal adhesions. amount of adhesions will be calculated in relation to previous surgery.

Eligibility criteria:
inclusion criteria: subjects operated for bowel obstruction -from january 1st 2006 to october 31st 2011 surgical codes for bowel obstruction: * intestinal adhesion with obstruction * other and unspecified intestinal obstruction * intestinal obstruction * unspecified and peritoneal adhesions surgical procedures identified for bowel obstruction: * division of band adhesion * adhesiolysis * other separation of adhesion during bowel obstruction * laparotomy and reposition or detorsion of intestine. exclusion criterias: -extra-peritoneal surgery such as inguinal or ventral hernia repair was excluded.
comparison of digital electronic stethoscope to computed tomography (ct) angiography in detection of coronary artery disease

Conditions: Coronary Artery Disease

Summary: the study is designed to evaluate the predictive diagnostic accuracy of sonomedica's cardiosond digital electronic stethoscope in the detection of coronary artery disease (cad) in patients without known disease who are referred to cardiac computed tomography angiography (ct scans).

the cardiosond is a completely noninvasive medical device which detects heart sounds and murmurs using ultrasensitive acoustic technology. the cardiosond produces a flow micro bruit score which is used to determine the likelihood of coronary artery disease. the cardiosond exam will be given to patients who agree to participate in the study upon signing of an informed consent form and prior to the administration of beta blocker agents and / or vasodilators as part of the normal cardiac ct angiography protocol. cardiosond data will be sent to an independent acoustic core lab which will determine data quality and produce a flow micro bruit score. ct angiography data will be analyzed by staff at north shore university hospital. a data review panel lead my the principal investigator will examine the results of both the cardiosond and ct angiography data to determine the accuracy of the cardiosond in detecting cad in the study population at large and in specific patient subgroups.

Eligibility criteria:
inclusion criteria: * subjects who are undergoing routine screening coronary ct angiography * willingness to sign informed consent form exclusion criteria: * inability to provide informed consent form * age less than 21 years * any contraindications to coronary ct angiography * known atherosclerotic heart disease, including a history of prior myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery or an established diagnosis of cad by prior x-ray or ct angiography * supraventricular or ventricular arrhythmias that would be expected to affect ct-angiography image quality (e.g., atrial fibrillation, atrial flutter, ventricular tachycardia, bigeminy, and trigeminy). patients with isolated premature atrial contractions and premature ventricular contractions may enroll. * use of intravenous vasodilators * any pulmonary conditions that would create abnormal physical findings that would interfere with the fidelity of the cardiac sound recording (e.g., obstructive pulmonary disease, such as asthma or copd, with audible wheezing). * presence of audible aortic or pulmonic diastolic murmurs, tricuspid or mitral flow diastolic murmurs, or continuous murmurs

Keywords: cad diagnostic
intubation of patients with an unstable cervical spine using the cmac device

Conditions: Laminectomy

Summary: the purpose of this study is to evaluate whether tracheal intubation with the cmac device decreases the time required for intubation as compared to intubation with the fiberoptic bronchoscope in patients with an unstable cervical spine. both the cmac device and the fiberoptic bronchoscope are currently commonly used in standard of care practices in the intubation of patients with cervical spine injury.


Eligibility criteria:
inclusion criteria: * patients with an unstable cervical-spine as a result of c-spine injury. * patients scheduled to undergo inpatient surgical procedures under general anesthesia. * willingness and ability to sign an informed consent document. * 18-80 years of age. * asa class i - iii adults of either sex exclusion criteria: * patients deemed to be at significant airway risk to necessitate awake fiber optic intubation. * patients with a history of oral-pharyngeal cancer or reconstructive surgery. * emergency surgeries. * any other conditions which may interfere with the conduct of the study.

Keywords: c-mac fiberoptic bronchoscope laryngoscopy cervical spine injury glottic view tracheal intubation
pre-operative staging of pancreatic cancer using superparamagnetic iron oxide magnetic resonance imaging (spio mri)

Conditions: Pancreatic Cancer

Summary: the purpose of this research study is to see if a specific kind of mri, called ultrasmall superparamagnetic iron oxide magnetic resonance imaging (uspio mri), which uses an fda-approved therapeutic agent(feraheme) to see if it is able to identify small and otherwise undetectable lymph node metastases in people who have pancreatic cancer and are scheduled for surgical resection.

* on the first day, study participants will undergo 2 mri examinations. a scan will be done prior to administration of the contrast agent (feraheme) and then a second scan immediately after administration. on the second day, study participants will be asked to return for a third mri. * all mri scans will be done at massachusetts general hospital.

Eligibility criteria:
inclusion criteria: * locally resectable pancreatic mass present on one or more pre-operative imaging modalities * must demonstrate no evidence of distant metastases as assessed by chest/abdomen/pelvis ct scan * deemed eligible for resection with curative intent by a treating surgeon who is listed as an investigator on this study * 18 years of age or older * no uncontrolled serious medical or psychiatric illness * women of childbearing potential must not be pregnant or lactating exclusion criteria: * known allergy to iron or dextran * pregnant or lactating * counter-indication to mri, such as the presence of metallic prostheses or implanted metal device * sickle cell disease or hemoglobinopathy

Keywords: spio mri feridex
an italian study of the efficacy of atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder (adhd) and comorbid oppositional defiant disorder (odd).

Conditions: Attention Deficit Hyperactivity Disorder; Oppositional Defiant Disorder

Summary: the study is a phase iiib multicentre, randomised, placebo controlled, trial in paediatric patients with attention-deficit/hyperactivity (adhd) and oppositional defiant disorder (odd). the primary aim of the study is to evaluate the efficacy of atomoxetine in improving adhd and odd symptoms in patients non responders to a previous psychological intervention with parent support. moreover, the potential role of atomoxetine in treating other psychiatric comorbid conditions associated with adhd and odd will be assessed.


Eligibility criteria:
inclusion criteria: * child or adolescent patients, male or female outpatients, who are at least 6 years of age, but must not yet have reached their 16th birthday prior to visit 1, when informed consent is obtained. * patients must meet diagnostic and statistical manual of mental disorders fourth edition (dsm-iv) diagnostic criteria for adhd (any subtype) and odd and score at least 1.5 standard deviations above the age norm for their diagnostic subtype using published norms for the swanson, nolan and pelham questionnaire: attention-deficit/hyperactivity disorder (snap-iv adhd) subscale score at both visit 1 and 2. * they must also have a snap-iv odd subscale score of at least 15 at both visit 1 and visit 2. * other comorbid conditions, are allowed but the diagnosis of adhd and odd must be the patient's primary diagnosis. * patients must be of normal intelligence in the judgment of the investigator (that is, without a general impairment of intelligence and likely, in the investigator's judgement, to achieve a score of greater than or equal to 70 on an intelligence quotient (iq) test). the administration of a formal iq test is not an entry requirement for the study. specific learning disabilities are not considered general impairment of intelligence. exclusion criteria: * patients who weigh less than 20 kilograms (kg) at study entry (visit 1). * patients who have a documented history of bipolar i or ii disorder, any history of psychosis or pervasive development disorder. * patients with a history of any seizure disorder (other than febrile seizures) or patients who have taken (or are currently taking) anticonvulsants for seizure control are not eligible to participate. * patients at serious suicidal risk as assessed by the investigator. * patients who, in the investigator's judgment, are likely to need psychotropic medications apart from the drug under the study, including health-food supplements that the investigator feels have central nervous system activity (for example, st. john's wort, melatonin).